Lyell Immunopharma, Inc.LYEL

Market cap

$10.4B

P/E ratio

	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	294	124	146	107
Marketable securities, current	321	517	401	265
Total cash & short-term investments	615	640	547	372
Total current assets	626	651	555	380
Property, plant and equipment, net	120	123	103	48
Marketable securities, non-current	284	70	17	13
Total non-current assets	501	286	195	111
Total assets	1,127	938	750	491
Accounts payable	3	4	5	5
Total current liabilities	47	37	35	54
Total non-current liabilities	151	67	61	54
Total liabilities	198	104	95	108
Common stock and paid-in capital	1,516	1,608	1,657	1,728
Retained earnings	-584	-767	-1,002	-1,345
Stockholders' equity	930	833	655	383